A Single Arm Phase II Trial of Circulating Tumor DNA-guided Adjuvant Therapy With Elacestrant in Hormone Receptor Positive HER2 Negative Breast Cancers at Risk for Late Recurrence (CATE)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Elacestrant (Primary)
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Jun 2025 Planned End Date changed from 1 Apr 2027 to 1 Jun 2027.
- 11 Jun 2025 Planned primary completion date changed from 1 Apr 2027 to 1 Jun 2027.
- 11 Jun 2025 Planned initiation date changed from 1 Apr 2025 to 1 Jun 2025.